BRPI0618473A2 - combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador - Google Patents
combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador Download PDFInfo
- Publication number
- BRPI0618473A2 BRPI0618473A2 BRPI0618473-1A BRPI0618473A BRPI0618473A2 BR PI0618473 A2 BRPI0618473 A2 BR PI0618473A2 BR PI0618473 A BRPI0618473 A BR PI0618473A BR PI0618473 A2 BRPI0618473 A2 BR PI0618473A2
- Authority
- BR
- Brazil
- Prior art keywords
- combinations
- methods
- oligodeoxynucleotide
- immunomodulatory
- immunomodulatory oligodeoxynucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Abstract
COMBINAçõES E MéTODOS DE USO DE UM OLIGODEOXINUCLEOTìDEO IMUNOMODULADOR. A presente invenção se refere às terapias de combinação para o tratamento de câncer. A combinação de agentes inclui oligonucleotídeos e um ou mais agentes quimioterápicos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73535105P | 2005-11-11 | 2005-11-11 | |
US73652705P | 2005-11-14 | 2005-11-14 | |
PCT/US2006/044003 WO2007059041A2 (en) | 2005-11-11 | 2006-11-13 | Combinations and methods of using an immunomodulatory oligodeoxynucleotide |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0618473A2 true BRPI0618473A2 (pt) | 2011-08-30 |
Family
ID=38049198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0618473-1A BRPI0618473A2 (pt) | 2005-11-11 | 2006-11-13 | combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090082295A1 (pt) |
EP (1) | EP1963502A4 (pt) |
JP (1) | JP2009515896A (pt) |
KR (1) | KR20080075107A (pt) |
AU (1) | AU2006315632A1 (pt) |
BR (1) | BRPI0618473A2 (pt) |
CA (1) | CA2628659A1 (pt) |
IL (1) | IL190983A0 (pt) |
RU (1) | RU2008118144A (pt) |
TW (1) | TW200824696A (pt) |
WO (1) | WO2007059041A2 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1716234B1 (de) * | 2004-02-20 | 2013-10-02 | Mologen AG | Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren |
EP2190440A1 (en) * | 2007-08-13 | 2010-06-02 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
WO2009105641A2 (en) | 2008-02-20 | 2009-08-27 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
JP5645840B2 (ja) | 2008-12-02 | 2014-12-24 | 株式会社Wave Life Sciences Japan | リン原子修飾核酸の合成方法 |
MX342945B (es) * | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
WO2011097384A2 (en) * | 2010-02-04 | 2011-08-11 | Board Of Regents, The University Of Texas System | Tumor targeted delivery of immunomodulators by nanoplymers |
GB2483462A (en) * | 2010-09-08 | 2012-03-14 | Mologen Ag | Use of a dumbbell-shaped DNA construct for the treatment of cancer through jet-injection administration |
WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
FR2975600B1 (fr) * | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
DK2734208T3 (en) | 2011-07-19 | 2017-06-19 | Wave Life Sciences Ltd | PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS |
WO2013023043A2 (en) * | 2011-08-10 | 2013-02-14 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy |
ES2862073T3 (es) | 2012-07-13 | 2021-10-06 | Wave Life Sciences Ltd | Grupo auxiliar asimétrico |
DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
CN104684923B (zh) | 2012-07-13 | 2018-09-28 | 株式会社新日本科学 | 手性核酸佐剂 |
WO2014172532A2 (en) * | 2013-04-17 | 2014-10-23 | Lowsky Robert | Methods for cancer treatment |
WO2015002861A1 (en) * | 2013-07-01 | 2015-01-08 | Fkd Holding Oy | Transfection of mesothelium body cavity lining with gene agents prior to chemotherapy to treat cancer |
WO2015022609A1 (en) * | 2013-08-14 | 2015-02-19 | Novartis Ag | Combination therapy for the treatment of cancer |
US10842969B2 (en) | 2013-10-25 | 2020-11-24 | Mercator Medsystems, Inc. | Systems and methods of treating malacia by local delivery of hydrogel to augment tissue |
AU2015204239B2 (en) * | 2014-01-06 | 2018-04-19 | Hackensack University Medical Center | Method for treating skin cancer using radiation therapy |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
AU2015207773B2 (en) | 2014-01-16 | 2021-06-17 | Wave Life Sciences Ltd. | Chiral design |
KR102598819B1 (ko) * | 2014-06-23 | 2023-11-03 | 더 제너럴 하스피탈 코포레이션 | 서열결정에 의해 평가된 DSB의 게놈 전체에 걸친 비편향된 확인 (GUIDE-Seq) |
JP6885867B2 (ja) | 2014-12-31 | 2021-06-16 | チェックメイト ファーマシューティカルズ, インコーポレイテッド | 組合せ腫瘍免疫療法 |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
CA3000816A1 (en) | 2015-09-11 | 2017-03-16 | The General Hospital Corporation | Full interrogation of nuclease dsbs and sequencing (find-seq) |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
KR20180053748A (ko) | 2015-09-30 | 2018-05-23 | 더 제너럴 하스피탈 코포레이션 | 시퀀싱(circle-seq)에 의한 절단 반응의 포괄적인 시험관내 보고 |
EP3672612A4 (en) | 2017-08-23 | 2021-09-29 | The General Hospital Corporation | MANIPULATED CRISPR-CAS9-NUCLEASES WITH CHANGED PAM SPECIFICITY |
EP3694993A4 (en) | 2017-10-11 | 2021-10-13 | The General Hospital Corporation | METHOD OF DETECTING A SITE-SPECIFIC AND UNDESIRED GENOMIC DESAMINATION INDUCED BY BASE EDITING TECHNOLOGIES |
US11898203B2 (en) | 2018-04-17 | 2024-02-13 | The General Hospital Corporation | Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents |
CN108486120B (zh) * | 2018-04-28 | 2019-12-06 | 新乡医学院 | 一种新型CpG ODN序列及其在抗黑色素瘤上的应用 |
EP4104830A1 (en) * | 2021-06-16 | 2022-12-21 | Burghardt Wittig | Sequential innate and adaptive immune modulation for cancer treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6943240B2 (en) * | 2000-09-15 | 2005-09-13 | Coley Pharmaceuticals Gmbh | Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist |
-
2006
- 2006-11-13 EP EP06837454A patent/EP1963502A4/en not_active Withdrawn
- 2006-11-13 CA CA002628659A patent/CA2628659A1/en not_active Abandoned
- 2006-11-13 BR BRPI0618473-1A patent/BRPI0618473A2/pt not_active Application Discontinuation
- 2006-11-13 KR KR1020087011159A patent/KR20080075107A/ko not_active Application Discontinuation
- 2006-11-13 RU RU2008118144/14A patent/RU2008118144A/ru not_active Application Discontinuation
- 2006-11-13 US US12/093,265 patent/US20090082295A1/en not_active Abandoned
- 2006-11-13 AU AU2006315632A patent/AU2006315632A1/en not_active Abandoned
- 2006-11-13 JP JP2008540250A patent/JP2009515896A/ja active Pending
- 2006-11-13 WO PCT/US2006/044003 patent/WO2007059041A2/en active Application Filing
- 2006-12-04 TW TW095144982A patent/TW200824696A/zh unknown
-
2008
- 2008-04-17 IL IL190983A patent/IL190983A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006315632A1 (en) | 2007-05-24 |
EP1963502A4 (en) | 2010-04-07 |
WO2007059041A2 (en) | 2007-05-24 |
WO2007059041A3 (en) | 2007-07-12 |
IL190983A0 (en) | 2009-08-03 |
EP1963502A2 (en) | 2008-09-03 |
CA2628659A1 (en) | 2007-05-24 |
KR20080075107A (ko) | 2008-08-14 |
JP2009515896A (ja) | 2009-04-16 |
US20090082295A1 (en) | 2009-03-26 |
RU2008118144A (ru) | 2009-11-20 |
TW200824696A (en) | 2008-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0618473A2 (pt) | combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador | |
CY1118760T1 (el) | Τροποποιημενα αντισωματα εναντι il-23 | |
GT200600035A (es) | Aminopiridinas como inhibidores de beta-secretasa | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
EA200801428A1 (ru) | Производные пиридиазинона для лечения опухолей | |
PA8667201A1 (es) | Nuevos compuestos farmaceuticos | |
ZA200709591B (en) | 2-amido-6-amino-8-oxopurine derivates as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C | |
TW200716141A (en) | Compositions and methods for treatment for neoplasms | |
EA200900781A1 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
BRPI0606112A2 (pt) | 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica | |
BRPI0811635A2 (pt) | Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos | |
CL2011001232A1 (es) | Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer | |
CL2007000311A1 (es) | Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer. | |
DK1863839T3 (da) | Acylerede GLP-1-forbindelser | |
CL2007002856A1 (es) | Compuestos derivados de pirazolo(1,5)pirimidina; composicion farmaceutica qu lo comprende;y su uso para tratar el cancer. | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
BRPI0810208A2 (pt) | Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer. | |
EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
CR9750A (es) | Dispersiones solidas amorfas de 7-cloro-n,n,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4h-prirdazino[4,5-b]indol-1-acetamida | |
BRPI0719559A2 (pt) | Uso de inibidores de iap para o tratamento de leucemia mieloide aguda | |
UY30451A1 (es) | 18-metil-19-nor-androst-4-en-17,17-espiroéteres (18-metil-19-nor-20-espirox-4-en-3-onas),ase como preparaciones farmacéuticas que lo contienen. | |
BRPI0718469A2 (pt) | Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto. | |
BRPI0818170A2 (pt) | 5-cianotienopiridinas para o tratamento de tumores. | |
WO2017187343A3 (en) | Nanoemulsions and methods for cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |